Concord Biotech Limited — PPTs, 10-08-2025: Investor Presentation

Here's a summary of Concord Biotech's investor presentation:

**Financial Highlights:**

Q1FY26 revenue dipped 5% to 204 Cr, attributed to customer procurement lumpiness. EBITDA fell 24% to 61 Cr (30.1% margin) and PAT 26% to 44 Cr. Margins were impacted by new injectable facility expenses; adjusted EBITDA margin, however, was 37%.

**Strategic Initiatives & Growth Drivers:**

Commenced commercial CDMO supply to a major US customer, signaling future revenue potential. Plans include broadening API portfolio, expanding injectable formulations, and increasing geographic reach. Focus on operational efficiencies and leveraging new facility capacity.

**Business Developments:**

Acquired 75% stake in US-based Stellon Biotech for US market entry. Formed wholly-owned Concord Lifegen for domestic sales. Dholka facility successfully passed USFDA, EU GMP, and Russian GMP inspections.

**Market Position & Competitive Advantage:**

Leader in niche fermentation-based APIs, a high-entry-barrier segment. Strength from 20+ years experience, large 1,250 m3 fermentation capacity, backward integration, and a robust 10+ product R&D pipeline.

**Investor Implications:**

Despite Q1 softness, strategic CDMO entry and market expansions point to positive growth potential. Management's confidence in scaling new facility revenue and improving future margins offers a favorable outlook.